Coronavirus Scientific Advisory Board (Turkey)

Opentrons Announces $200 Million Series C Round Led by SoftBank Vision Fund 2

Thursday, September 23, 2021 - 1:00pm

Today Opentrons Labworks Inc. has announced SoftBank Vision Fund 2* has led the companys $200 million Series C investment with participation by Khosla Ventures.

Key Points: 
  • Today Opentrons Labworks Inc. has announced SoftBank Vision Fund 2* has led the companys $200 million Series C investment with participation by Khosla Ventures.
  • The Series C round will enable significant investment in the Opentrons platform.
  • OPENTRONS ANNOUNCES KEY TEAM ADDITIONS TO SCALE PLATFORM:
    Myrtle Potter, Chair of the Board of Opentrons Labworks, Inc. Myrtle is currently CEO of Sumitovant.
  • *As of the date of this press release, SoftBank Group Corp. has made capital contributions to allow investments by SoftBank Vision Fund 2 ("SVF 2") in certain portfolio companies.

Garuda Therapeutics Launches with $72 Million Series A Financing

Thursday, September 23, 2021 - 1:00pm

Garuda is developing the worlds first, off-the-shelf hematopoietic stem cell platform that will eliminate dependency on donor or patient cells.

Key Points: 
  • Garuda is developing the worlds first, off-the-shelf hematopoietic stem cell platform that will eliminate dependency on donor or patient cells.
  • Currently, patients seeking a blood stem cell transplant, must find a suitable human donor as a source of blood stem cells.
  • Our technology has the potential to transform blood stem cell transplants, revolutionizing the landscape of medicine, said Dhvanit Shah, Ph.D., Co-Founder, President and CEO of Garuda Therapeutics.
  • Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants.

AnHeart Therapeutics Announces Formation of Scientific Advisory Board

Wednesday, September 22, 2021 - 1:00pm

AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, announced today the formation of its Scientific Advisory Board (SAB) comprised of world-renowned oncologists to provide external scientific review and high-level counsel on the Companys research and development programs.

Key Points: 
  • AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, announced today the formation of its Scientific Advisory Board (SAB) comprised of world-renowned oncologists to provide external scientific review and high-level counsel on the Companys research and development programs.
  • We are excited and privileged to have the opportunity to work with this group of leading oncologists on the development of our pipeline, said Bing Yan, M.D., CMO and Co-founder of AnHeart Therapeutics.
  • We look forward to their continued contributions as AnHeart enters a new stage in advancing taletrectinib into late-stage clinical trials this year."
  • AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need.

BlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board

Tuesday, September 21, 2021 - 12:00pm

BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.

Key Points: 
  • BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.
  • The members of the BlueWillow Biologics SAB include:
    Robin Isaacs, M.D.
  • Prior, he held positions of increasing responsibility at Merck & Co., Inc., most recently serving as Vice President and Therapeutic Area Head, Vaccine Clinical Research.
  • We are proud to have such a distinguished team of scientific experts serve as members of our Scientific Advisory Board, underscoring their belief in our intranasal vaccines to elicit mucosal immunity, commented Chad Costley, M.D., President and Chief Executive Officer of BlueWillow Biologics.

Foundation Fighting Blindness to Jointly Host Online Continuing Medical Education (CME, COPE) Webinar

Tuesday, September 21, 2021 - 12:00pm

COLUMBIA, Md., Sept. 21, 2021 /PRNewswire/ --The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, will host an online continuing medical education (CME and COPE) course on Tuesday, October 26, 2021, at 7:00 p.m.

Key Points: 
  • COLUMBIA, Md., Sept. 21, 2021 /PRNewswire/ --The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, will host an online continuing medical education (CME and COPE) course on Tuesday, October 26, 2021, at 7:00 p.m.
  • The continuing education course will enable eye care professionals to:
    Describe and contrast the clinical presentations of the different forms of macular degeneration.
  • This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC and Foundation Fighting Blindness.
  • Established in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research.

Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board

Monday, September 20, 2021 - 1:00pm

Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.

Key Points: 
  • Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.
  • The new additional Aviceda Scientific Advisory Board members includes:
    Aviceda is honored and privileged to add new world-class scientists and renowned researchers to join our efforts in developing the next generation of glyco-immune therapeutics for the treatment of immune-dysfunction conditions, said Mohamed A. Genead, MD, Co-Founder & President of Aviceda Therapeutics.
  • She published more than 280 scientific papers in well recognized journals (Cell, Nature, Nature Immunology, PNAS, and JEM) and supervised 29 PhD students.
  • The Aviceda team is already building on the foundational work in the emerging field of glycobiology to develop potential therapeutics and interventional strategies.

PhotoPharmics Brings Renowned Experts in Parkinson’s Disease and Other Neurodegenerative Diseases to Advisory Board

Thursday, September 16, 2021 - 4:00pm

Clinical-stage medical device maker PhotoPharmics today announced a Clinical & Scientific Advisory board (CSAB) comprised of six leading experts in Parkinsons disease (PD) and other neurodegenerative diseases.

Key Points: 
  • Clinical-stage medical device maker PhotoPharmics today announced a Clinical & Scientific Advisory board (CSAB) comprised of six leading experts in Parkinsons disease (PD) and other neurodegenerative diseases.
  • The boards aim is to provide clinical and scientific advice and direction to support the PhotoPharmics mission to "Improve the lives of people who suffer from neurodegenerative diseases.
  • We are extremely pleased that Dr. Olanow has agreed to chair our Advisory Board, said Kent Savage, CEO of PhotoPharmics.
  • As an emerging leader in non-invasive specialized light therapy for neurodegenerative diseases, PhotoPharmics will benefit from the advice and insight of this world-class advisory board, said Karl Kieburtz, MD, Chief Medical Officer of PhotoPharmics.

Drs. Anil Vachani and Claudio Scafoglio Awarded LUNGevity Foundation 2021 Early Detection Awards

Thursday, September 16, 2021 - 12:10pm

WASHINGTON, Sept. 16, 2021 /PRNewswire/ --LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization and the only lung cancer organization with a programmatic focus on early detection, announced today the recipients of its 2021 Early Detection Awards (EDAs) for lung cancer research.

Key Points: 
  • WASHINGTON, Sept. 16, 2021 /PRNewswire/ --LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization and the only lung cancer organization with a programmatic focus on early detection, announced today the recipients of its 2021 Early Detection Awards (EDAs) for lung cancer research.
  • These awards support translational research projects directed at new approaches to improve clinical methods for the detection and diagnosis of lung cancer.
  • LUNGevity is proud to support the following 2021 Early Detection Award projects:
    Anil Vachani, MD, University of Pennsylvania Optimizing biomarker based strategies for lung cancer screening.
  • Claudio Scafoglio, MD, PhD, University of California, Los Angeles Pilot study of SGLT2 in the characterization of early lung adenocarcinoma.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

Wednesday, September 15, 2021 - 9:56pm

Research and development (R&D) expenses were $4.4 million for the fourth quarter of fiscal 2021, compared to $2.4 million for the same period in fiscal 2020.

Key Points: 
  • Research and development (R&D) expenses were $4.4 million for the fourth quarter of fiscal 2021, compared to $2.4 million for the same period in fiscal 2020.
  • Full fiscal year 2021 R&D expenses were $15.0 million, compared to $14.5 million in fiscal year 2020.
  • General and administrative (G&A) expenses were $2.2 million for the fourth quarter of fiscal 2021, compared to $1.1 million for the same period in fiscal 2020.
  • Full fiscal year 2021 G&A expenses were $7.9 million, compared to $6.1 million in fiscal year 2020.

Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer

Wednesday, September 15, 2021 - 8:00am

HELSINKI and LONDON, Sept. 15, 2021 /PRNewswire/ --Rappta Therapeutics ("Rappta"), which is focused on developing first-in-class anti-cancer drugs reactivating protein phosphatase 2A (PP2A), announces today the appointment of Sunjeet Sawhney as Chief Executive Officer (CEO) with immediate effect.

Key Points: 
  • HELSINKI and LONDON, Sept. 15, 2021 /PRNewswire/ --Rappta Therapeutics ("Rappta"), which is focused on developing first-in-class anti-cancer drugs reactivating protein phosphatase 2A (PP2A), announces today the appointment of Sunjeet Sawhney as Chief Executive Officer (CEO) with immediate effect.
  • Rappta's Co-founder and Founding CEO Mikko Mannerkoski will move to be Chief Financial Officer (CFO) as planned.
  • Sunjeet holds a MSc in Immunology from the University of London and will be based in London, UK.
  • Sunjeet Sawhney, CEO of Rappta Therapeutics, commented: "I am honored to have been given the opportunity to lead Rappta.